Novartis to face PD1 competition for Mekinist and Tafinlar combo
This article was originally published in Scrip
The $20bn Novartis-GSK mega deal has brought the Swiss firm new opportunities this week as the European Medicines Agency announced CHMP positive opinions for Tafinlar (dabrafenib) and Mekinist (trametinib) as well as Revoldade (eltrombopag). However, Datamonitor Healthcare believes that sales of the melanoma combo in unlikely to be transformational for the market or the company thanks to pricing pressures and competition from anti-PD1s.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.